Buparlisib (BKM120) Mechanism of Action: PI3K Inhibition in Breast Cancer Cells Research

Buparlisib (BKM120) MOA:Targeting PI3K/PI3K-AKT-mTOR for Breast Cancer

🎯 check Buparlisib (BKM120) product page

Buparlisib (BKM120) is a potent, selective, ATP-competitive pan-PI3K inhibitor. It affects the PI3K/AKT/mTOR signaling pathway by downregulating AKT phosphorylation, effectively inhibiting tumor cell proliferation and inducing apoptosis.

Primary Applications and Mechanism of Action